Hematology News and Research

RSS

Hematology, also spelled haematology, is the branch of biology (physiology), pathology, clinical laboratory, internal medicine, and pediatrics that is concerned with the study of blood, the blood-forming organs, and blood diseases. Hematology includes the study of etiology, diagnosis, treatment, prognosis, and prevention of blood diseases.

Major development in re-treatment with CAR T therapy

At the American Society of Hematology (ASH) Annual Meeting in 2022 (Abstract 2016), researchers from the Abramson Cancer Center at the University of Pennsylvania presented preliminary findings from an ongoing Phase I clinical trial demonstrating effective re-treatment with CAR T cell therapy for patients whose cancers relapsed after prior CAR T therapy.

12 Dec 2022

UC San Diego Alpha Clinic awarded $8 million to bring new stem cell-based therapies to patients

Stem cells show particular promise in treating diseases for which few other effective treatments exist.

25 Nov 2022

Regeneration of the immune system in MS patients

Transplanting blood stem cells is a new but incredibly successful treatment for multiple sclerosis. Now, a study directed by the University of Zurich has looked closely at how the autoimmune disease is controlled by the treatment and how the immune system recovers afterward.

14 Nov 2022

UC Davis launches new center to accelerate the development of promising cancer therapies

UC Davis Comprehensive Cancer Center has launched a Center for Experimental Therapeutics in Cancer to accelerate promising cancer therapies from the lab to the bedside.

From The University of California, Davis 10 Oct 2022

Researchers analyze the significance of cellular interactions for lung cancer

A new Cleveland Clinic study has uncovered vital information about the cellular interaction of tumor cells and normal tissue, leading to a better understanding of how therapeutic resistance evolves.

5 Jul 2022

Researchers discover effective therapy for pediatric T-acute leukemia

The most frequent type of malignancy in kids is acute lymphoblastic leukemia (ALL).

27 Jun 2022

Researchers understand the mystery behind DNA rings

Professor Dr Anton Henssen of Charité – Universitätsmedizin Berlin and the Helmholtz Association’s Max Delbrück Center (MDC) for Molecular Medicine, along with a group of researchers from the United States and the United Kingdom, have received a grant for a Cancer Grand Challenge.

17 Jun 2022

Drugs used for myelodysplastic syndrome could potentially activate a sleeping oncogene

Hypomethylating agents (HMA) are currently used as a first-line treatment for patients with myelodysplastic syndrome (MDS) - a group of disorders where there is insufficient production of healthy mature blood cells in the bone marrow - and increasingly in other diseases, but their mechanism of action remains unclear.

From National University of Singapore (NUS) 27 May 2022

Researchers analyze the body’s immune cells with blood cancer cells

One in every two people will acquire cancer at some point in their lives, according to the most recent international estimate.

19 Apr 2022

Biologists unravel the mystery behind nuclear anomaly in blood cancer cells

The mystery is being unraveled of why the control centers, or nuclei, of certain blood cancer cells have a distinctly odd shape.

5 Apr 2022

Researchers discover abnormal gene mutations that lead to cancer development

The reason why the control centers, or nuclei, of certain blood cancer cells, have a peculiar structure is still a mystery.

1 Apr 2022

Scientists elucidate mechanism that causes treatment resistance in aggressive pancreatic cancer

Drug resistance is a major obstacle in the treatment of cancers. In an aggressive type of pancreatic cancer, for instance, drug resistance is associated with the suppression of programmed cell death, which results in the uncontrolled growth of cancer cells.

25 Feb 2022

Researchers discover a crucial and exploitable vulnerability in diffuse large B cell lymphomas

Aggressive and relatively common lymphomas called diffuse large B cell lymphomas (DLBCLs) have a critical metabolic vulnerability that can be exploited to trick these cancers into starving themselves, according to a study from researchers at Weill Cornell Medicine and Cornell's Ithaca campus.

4 Jan 2022

Study targets metabolic pathways to identify sensitivities among cancer cells

Metabolic reprogramming, accepted as a hallmark of cancer, might indicate a vulnerability to be used by targeted cancer therapy.

17 Dec 2021

Scientists find how cells remain dormant for years before awakening to create metastatic cancer

Mount Sinai researchers have solved a major mystery in cancer research: How cancer cells remain dormant for years after they leave a tumor and travel to other parts of the body, before awakening to create metastatic cancer.

14 Dec 2021

High-risk lymphoma patients may receive durable benefit from axi-cel CAR T cell therapy

Three clinical studies led by researchers at The University of Texas MD Anderson Cancer Center demonstrated enhanced responses for patients with high-risk lymphoma treated with axicabtagene ciloleucel (axi-cel) chimeric antigen receptor (CAR) T cell therapy.

13 Dec 2021

Genetic makeup of neuroblastoma shows marked spatial and temporal variability

Tumors are heterogeneous, which means that different parts of the same tumor can be genetically distinct. This phenomenon, known as intratumor heterogeneity, is steadily gaining in significance within the field of cancer research.

13 Dec 2021

Researchers identify a new approach to triggering differentiation in acute myeloid leukemia

In the late 1980s, scientists developed a revolutionary approach to treating acute myeloid leukemia (AML), a type of blood cancer. Called differentiation therapy, it amounted to a bona fide cure for many patients.

2 Dec 2021

Next-generation sequencing for minimal residual disease proven more sensitive than flow cytometry

In pediatric and young adult patients with acute lymphoblastic leukemia (ALL) treated with tisagenlecleucel (Kymriah), DNA sequencing-based detection of residual disease between three and 12 months accurately identified all patients who would eventually relapse, while other methods were less predictive.